Cargando…

Risk assessment model for first-cycle chemotherapy-induced neutropenia in patients with solid tumours

LÓPEZ-POUSA A., RIFÀ J., CASAS DE TEJERINA A., GONZÁLEZ-LARRIBA J.L., IGLESIAS C., GASQUET J.A. & CARRATO A. (2010) European Journal of Cancer Care Risk assessment model for first-cycle chemotherapy-induced neutropenia in patients with solid tumours Chemotherapy-induced neutropenia, the major do...

Descripción completa

Detalles Bibliográficos
Autores principales:	LÓPEZ-POUSA, A, RIFÀ, J, CASAS DE TEJERINA, A, GONZÁLEZ-LARRIBA, JL, IGLESIAS, C, GASQUET, JA, CARRATO, A
Formato:	Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2010
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3082427/ https://www.ncbi.nlm.nih.gov/pubmed/20088918 http://dx.doi.org/10.1111/j.1365-2354.2009.01121.x

Ejemplares similares

Prognostic Value of Chemotherapy-Induced Neutropenia at the First Cycle in Invasive Breast Cancer
por: Ma, Rui-Min, et al.
Publicado: (2016)

Validation of the FENCE Risk Groups for Prediction of Febrile Neutropenia With First-Cycle Chemotherapy
por: Zatarah, Razan, et al.
Publicado: (2022)

Neutropenia management and granulocyte colony-stimulating factor use in patients with solid tumours receiving myelotoxic chemotherapy—findings from clinical practice
por: Krzemieniecki, K., et al.
Publicado: (2013)

A nomogram for predicting complications in patients with solid tumours and seemingly stable febrile neutropenia
por: Fonseca, Paula Jiménez, et al.
Publicado: (2016)

Chemotherapy-induced neutropenia and febrile neutropenia in patients with gynecologic malignancy
por: Hashiguchi, Yasunori, et al.
Publicado: (2015)

The reliability of FEbrile Neutropenia after ChEmotherapy (FENCE) scores in predicting granulocyte colony-stimulating factor breakthrough febrile neutropenia among patients with lymphoma undergoing first-cycle chemotherapy: A prospective observational study
por: Thungthong, Pravinwan, et al.
Publicado: (2023)

Pegfilgrastim and daily granulocyte colony-stimulating factor: patterns of use and neutropenia-related outcomes in cancer patients in Spain – results of the LEARN Study
por: ALMENAR, D, et al.
Publicado: (2009)

Role of lipegfilgrastim in the management of chemotherapy-induced neutropenia
por: Hoggatt, Jonathan, et al.
Publicado: (2015)

XM02 is superior to placebo and equivalent to Neupogen™ in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy
por: del Giglio, A, et al.
Publicado: (2008)

Chemotherapy Induced Neutropenia, Febrile-Neutropenia and Determinants Among Solid Cancer Patients Attending Oncology Unit of a Tertiary Care Teaching Hospital in Ethiopia
por: Dessalegn, Mekonnen, et al.
Publicado: (2023)

Validation of the (CSR)FENCE score for prediction of febrile neutropenia during chemotherapy cycles 2–6
por: Zatarah, Razan, et al.
Publicado: (2022)

Management of chemotherapy-associated febrile neutropenia
por: Cameron, D
Publicado: (2009)

The Potential Contribution of Dental Foci and Oral Mucositis to Febrile Neutropenia in Patients Treated With Myelosuppressive Chemotherapy for Solid Tumors and Lymphoma
por: Zecha, Judith A. E. M., et al.
Publicado: (2022)

Neutropenia Prediction Based on First-Cycle Blood Counts Using a FOS-3NN Classifier
por: Shirdel, Elize A., et al.
Publicado: (2011)

Chemotherapy-Induced Neutropenia and Febrile Neutropenia in the US: A Beast of Burden That Needs to Be Tamed?
por: Boccia, Ralph, et al.
Publicado: (2022)

Cost analysis of skeletal-related events in Spanish patients with bone metastases from solid tumours
por: Durán, I., et al.
Publicado: (2013)

Properdin Levels in Individuals with Chemotherapy-Induced Neutropenia
por: Tsyrkunou, Artsiom, et al.
Publicado: (2016)

Neutropenia during the First Cycle of Induction Chemotherapy Is Prognostic for Poor Survival in Locoregionally Advanced Nasopharyngeal Carcinoma: A Real-World Study in an Endemic Area
por: Xu, Cheng, et al.
Publicado: (2018)

Giant cell tumour of bone: new treatments in development
por: López-Pousa, A., et al.
Publicado: (2015)

Predictors of Septic Shock or Bacteremia in Children Experiencing Febrile Neutropenia Post-Chemotherapy
por: Avilés-Robles, Martha, et al.
Publicado: (2022)

Chemotherapy induced neutropenia and febrile neutropenia among breast cancer patients in a tertiary hospital in Nigeria
por: Salako, Omolola, et al.
Publicado: (2021)

Development and validation of a prediction model for the risk of developing febrile neutropenia in the first cycle of chemotherapy among elderly patients with breast, lung, colorectal, and prostate cancer
por: Hosmer, Wylie, et al.
Publicado: (2010)

Prolonged severe neutropenia after the first daratumumab administration for multiple myeloma with baseline neutropenia
por: Nakamura, Fumihiko, et al.
Publicado: (2019)

Neutropenia and Neutropenic Complications in ABVD Chemotherapy for Hodgkin Lymphoma
por: Vakkalanka, Bhanu, et al.
Publicado: (2011)

Role of lipegfilgrastim in the management of chemotherapy-induced neutropenia [Corrigendum]
Publicado: (2015)

Lipegfilgrastim in the management of chemotherapy-induced neutropenia of cancer patients
por: Guariglia, Roberto, et al.
Publicado: (2016)

Neutropenia
por: Mithoowani, Siraj, et al.
Publicado: (2022)

Medical visits for chemotherapy and chemotherapy-induced neutropenia: a survey of the impact on patient time and activities
por: Fortner, Barry V, et al.
Publicado: (2004)

Wnt and Vitamin D at the Crossroads in Solid Cancer
por: González-Sancho, José Manuel, et al.
Publicado: (2020)

Baseline and early lymphopenia predict for the risk of febrile neutropenia after chemotherapy
por: Ray-Coquard, I, et al.
Publicado: (2003)

The pharmacologic basis of high dose chemotherapy with haematopoietic stem cell support for solid tumours
por: Porrata, L F, et al.
Publicado: (2001)

Biosimilar filgrastim treatment patterns and prevention of febrile neutropenia: a prospective multicentre study in France in patients with solid tumours (the ZOHé study)
por: Roché, Henri, et al.
Publicado: (2018)

Efficacy and safety of the administration of bevacizumab in combination with first-line chemotherapy for the treatment of advanced breast carcinoma: ATHENA MO19391 study results in Spanish patients
por: Ciruelos, EM, et al.
Publicado: (2009)

Pasteurella multocida Bacteremia in a Patient With Ovarian Cancer and Chemotherapy-induced Neutropenia
por: Casey, A. Catherine, et al.
Publicado: (1995)

Neutropenia: occurrence and management in women with breast cancer receiving chemotherapy
por: do Nascimento, Talita Garcia, et al.
Publicado: (2014)

New developments in the treatment of chemotherapy-induced neutropenia: focus on balugrastim
por: Ghidini, Michele, et al.
Publicado: (2016)

Towards Quantitative Systems Pharmacology Models of Chemotherapy‐Induced Neutropenia
por: Craig, M
Publicado: (2017)

Chemotherapy-Induced Neutropenia in Pediatric Leukemia: Persian Medicine Perspective
por: Daneshfard, Babak, et al.
Publicado: (2019)

Update on Febrile Neutropenia in Pediatric Oncological Patients Undergoing Chemotherapy
por: Cennamo, Federica, et al.
Publicado: (2021)

Serum protein and electrolyte imbalances are associated with chemotherapy induced neutropenia
por: Abbasi, Benazir, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_68rih607e7s9aflchsjacl85ut